Miklos Szolics
Central America
Research Article
The Rapidly Changing Landscape of Multiple Sclerosis Immunomodulatory Therapy: A Retrospective Chart Review in the United Arab Emirates
Author(s): Nicoline Schiess, Kathryn Brown Holroyd, Katherine Huether, Miklos Szolics and Taoufik AlsaadiNicoline Schiess, Kathryn Brown Holroyd, Katherine Huether, Miklos Szolics and Taoufik Alsaadi
The past 6 years have demonstrated a dramatic change in the landscape of immunomodulatory treatment for multiple sclerosis. Prior to 2010, there were no approved FDA oral immunomodulatory medications available. Since then, three new oral medications have been approved in addition to the newly approved alemtuzumab and ocrelizumab. This has dramatically changed the treatment options for MS patients. The older injectable agents – beta-interferons and glatiramer acetate are slowly being replaced. While data exists in the literature regarding the use of new medications in the west, there is little published data about the use of these new medications in the Middle East and, none, to our knowledge, in the United Arab Emirates (UAE). We conducted a retrospective chart review of four major government hospitals in Abu Dhabi looking at the types of MS in the Emirate, the use of different .. Read More»
DOI:
10.4172/2376-0389.1000203
